Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide

被引:25
作者
Girgis, M
Hallemeier, C
Blum, W
Brown, R
Lin, HS
Khoury, H
Goodnough, LT
Vij, R
Devine, S
Wehde, M
Postma, S
Oza, A
DiPersio, J
Adkins, D
机构
[1] Washington Univ, Sch Med, Div Oncol,Dept Internal Med, Sect Bone Marrow Transplantat & Leukemia, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Radiol, Div Radiat Oncol, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Pathol, Div Lab Med,Siteman Canc Ctr, St Louis, MO 63110 USA
关键词
D O I
10.1182/blood-2003-07-2346
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We hypothesized that low-dose (550-cGy), single-exposure, high dose rate (30 cGy/ min) total body irradiation (TBI) with cyclophosphamide as conditioning for HLA-compatible unrelated donor (URD) bone marrow transplantation (BMT) would result in donor chimerism (DC) with a low risk for serious organ toxicity and treatment-related mortality (TRM). Twenty-six patients with good risk diagnoses (acute leukemia in first complete remission [CR] and chronic-phase chronic myelogenous leukemia [CML]) and 84 with poor risk diagnoses underwent this regimen and URD BMT Unsorted marrow nucleated cells were assessed for chimerism, using VNTR probes. All DC occurred in 78 (86%) of 91 evaluable patients at 1 or more follow-up points. Graft failure occurred in 7 (7.7%) patients. Fatal organ toxicity occurred in only 2% of patients. TRM rates through 2 years of follow-up were 19% and 42% in those with good and poor risk diagnoses, respectively. Overall and disease free survival rates in the good risk group were 47% and 40%, respectively, and in the poor risk group they were 25% and 21%, respectively, at a median follow-up for living patients of 850 days (range, 354-1588 days). This regimen resulted in 100% DC in most patients undergoing URD BMT with a relatively low risk for fatal organ toxicity and TRM. (c) 2005 by The American Society of Hematology.
引用
收藏
页码:3035 / 3041
页数:7
相关论文
共 44 条
[1]   Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: Recommendations from a Workshop at the 2001 Tandem Meetings [J].
Antin, JH ;
Childs, R ;
Filipovich, AH ;
Giralt, S ;
Mackinnon, S ;
Spitzer, T ;
Weisdorf, D .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (09) :473-485
[2]   Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. [J].
Bensinger, WI ;
Martin, PJ ;
Storer, B ;
Clift, R ;
Forman, SJ ;
Negrin, R ;
Kashyap, A ;
Flowers, MED ;
Lilleby, K ;
Chauncey, TR ;
Storb, R ;
Appelbaum, FR ;
Rowley, S ;
Heimfeld, S ;
Blume, K .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (03) :175-181
[3]   Low-dose (550 cGy), single-exposure total body irradiation and cyclophosphamide: Consistent, durable engraftment of related-donor peripheral blood stem cells with low treatment-related mortality and fatal organ toxicity [J].
Blum, W ;
Brown, R ;
Lin, HS ;
Zehnbauer, B ;
Khoury, H ;
Goodnough, LT ;
Westervelt, P ;
Vij, R ;
DiPersio, J ;
Adkins, D .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (11) :608-618
[4]  
Bornhäuser M, 2001, CLIN CANCER RES, V7, P2254
[5]   Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program [J].
Castro-Malaspina, H ;
Harris, RE ;
Gajewski, J ;
Ramsay, N ;
Collins, R ;
Dharan, B ;
King, R ;
Deeg, HJ .
BLOOD, 2002, 99 (06) :1943-1951
[6]   Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses [J].
Childs, R ;
Clave, E ;
Contentin, N ;
Jayasekera, D ;
Hensel, N ;
Leitman, S ;
Read, EJ ;
Carter, C ;
Bahceci, E ;
Young, NS ;
Barrett, AJ .
BLOOD, 1999, 94 (09) :3234-3241
[7]  
COMELISSEN JJ, 2001, BLOOD, V97, P1572
[8]  
Common Toxicity Criteria, 1998, COMM TOX CRIT VERS 2
[9]  
Davies SM, 2000, BLOOD, V96, P4096
[10]   Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective, randomized trial [J].
Deeg, HJ ;
Lin, DY ;
Leisenring, W ;
Boeckh, M ;
Anasetti, C ;
Appelbaum, FR ;
Chauncey, TR ;
Doney, K ;
Flowers, M ;
Martin, P ;
Nash, R ;
Schoch, G ;
Sullivan, KM ;
Witherspoon, RP ;
Storb, R .
BLOOD, 1997, 89 (10) :3880-3887